CeeD – where ‘know how’ meets ‘can do’

    You are here

    • You are here:
    • Home > Renishaw Diagnostics

Renishaw Diagnostics

Renishaw Diagnostics has developed the RenDx® Multiplex Assay System, a PCR based platform that provides an aid to diagnosis of infectious disease. The system provides automated, multiplex, high sensitivity in vitro testing using novel, patented detection technology, based on surface enhanced resonance Raman scattering (SERRS).

The platform’s first assay, Fungiplex, detects the most common causative agents of invasive fungal disease, a significant cause of morbidity and mortality in patients who receive immunosuppressive therapies, such as those undergoing solid organ or hematopoietic stem cell transplants. The assay can identify 12 candida and aspergillus species directly from whole blood and serum samples, eliminating the need for culture and providing results within hours.

Renishaw Diagnostics Limited is part of the Renishaw Group, a world leader in engineering, medical device and spectroscopy technologies. A global company, Renishaw’s products are used in such diverse applications as machine tool automation, additive manufacturing and medical technologies. Founded in 1973, Renishaw now has over 4,000 staff in 33 countries around the world. Renishaw Diagnostics is part of the Group’s growing focus and expansion into the healthcare sector.